A quieter week for product updates from the EMA, but still some interesting new announcements worth nothing Two new products launched, one novel treatment, and a diagnostic. The final new product registration of note is the latest Stelara biosimilar to

PharmaFootpath currently shares details on the latest EMA product registration updates through Linkedin, but will start to share through a newsletter too. As subscribers to our company updates, I've added you here too, but feel free to unsubsribe

I'm pleased now to be returning to expanding our data to new markets, with Finland the latest addition! (Adding Lapland and Santa at this time of year felt appropriate!) Earlier this year we were adding new markets regularly,

Hello! I'll be heading to ExpoPharm in Munich on the 10th and 11th of October, if you'll be attending please let me know and we can have a catch up! I've plenty of developments

When searching through Pharma Footpath for a product you may not have sourced very often, or even entirely new, you can sometimes find that a suprising price in a market you don't have strong relationships. What then? Using

Some markets are more difficult to gather detailed information from, and the Italian market falls in that category. That means that when we do run analytics on the market, it's important to share! - 1,482 parallel trade